Summit Therapeutics is holding company. Through its subsidiaries, Co. is a biopharmaceutical company focused on the discovery, development, and commercialization of medicinal therapies. Co.'s ivonescimab is a bispecific antibody that combines the benefits of immunotherapy via a blockade of PD-1 with the anti-angiogenesis benefits of an anti-vascular endothelial growth factor into a single molecule. Co. also focuses on ridinilazole, its product candidate for treating patients suffering from Clostridioides difficile infection. Co.'s other product candidate, SMT-738, is in development for combating multidrug resistant infections, specifically carbapenem-resistant Enterobacteriaceae infections.